Ark's Cerepro meets endpoint in pivotal brain cancer trial
This article was originally published in Scrip
Executive Summary
Ark Therapeutics' novel gene-based therapy, Cerepro, has met its primary endpoint in its pivotal Phase III trial in newly-diagnosed brain cancer, preliminary trial results show.